• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:WO1984000547A1
    申请号:PCT/EP1983/000193
    申请日:1983-07-23
    公开日:1984-02-16
    发明作者:Ching Pong Mak；Hans Fliri
    申请人:Sandoz Ag；
    IPC主号:C07D477-00
    专利说明:
    [0001] FLUORALKYLATEDCARBAPENEM DERIVATIVES
    [0002] The present invention concerns 6-(1'-fluorethyl )- and 6-(1'-fluoro-1'-methylethyl )-carbaμenems, processes for their production and their use as chemotherapeutics.
    [0003] EPA1628 discloses a very wide ränge of carbapenem derivatives having antibiotic activity but makes no mention of the fluoralkylated compounds of the present invention and their advantageous antibiotic properties.
    [0004] More particularly the invention concerns compounds of formula I
    [0005]
    wπerein, R1 represents hydrogen or methyl and
    [0006] R2 represents hydrogen or lower alkyl, lower alkenyl er cyclo- alkyl each of which may be unsubstituted or mono- or polysubstituted by amino, mono- or di-(lower)-alkylamino, lower acylamino, carboxy, lower alkoxycarbonyl or carbamoyl; a group of formula IIc
    [0007] (CH2)p-R7 IIc wherein R7 represents phenyl or a 5- or 6-membered saturated or unsaturated heterocycle containing one or more heteroatoms selected from O, S and/or N and which may be unsubstituted or mono- or polysubstituted by fluαro, chloro, brorno, amino, mono- or di-(lower)-alkylamino, hydroxy, lower alkoxy, mercapto, alkyl thio, phenylthio, sulfamoyl, guanidino, nitro, cyano, lower acylamino, carboxy , alkoxycarbonyl or carbamoyl and p is 0, 1, 2 or 3; or a group of formula


    [0008] wherein R4, R5 and R6 mav be the same or different and each represents hydrogen or lower alkyl or R4 and R6 and/or R5 and one of the CH2 groups may be joined to form a ring as may R5 and R6 in formula II and R4 and R5 in Ila and
    [0009] Ilb, which rings may be unsubstituted or mono- or poly-substituted by alkyl, hydroxy, carboxy or di-(lower)-alkyl- amino, m is 2 or 3, and n is 1 , 2 or 3 with the proviso that when R1 is hydrogen and the group containing it has R-configuration, R2 is other than acetylaminoethyl; or protected forms and/or physiologically- hydrolysable and acceptable ester forms thereof; in free acid or salt form or in the form of zwitter-ions.
    [0010] The compounds cf the invention may be prepared A) by introducing a group -S-R2 into a compound of formula III
    wherein R1 and R2 are as defined above, R8 represents a leaving group
    [0011] R3 represents a protecting group or a physiologi cally hydrolysable and acceptable ester group or
    [0012] B) by exchanging the OH group in a compound of formula IV
    [0013]
    or a precursor thereof for fluoro, whereby in formula IV, R1 , R2 and
    [0014] R3 are as defined above, and if required deprotecting a compound thus obtained or if required converting a compound thus obtained into or into another physiologically hydrolysable - and acceptable - ester form and/or protected form thereof and recovering the compound thus obtained in free acid or salt form or in the form of a zwitterion.
    [0015] Process A) may be carried out in conventional manner for example in an inert solvent such as an aromatic hydrocarbon e.g. benzene; or acetonitrile and preferably at reduced temperatures e.g. ca 0°C.
    [0016] Process B) may be carried out in conventional manner e.g. employing a dialkylaminosulfurtrifluoride such as diethylaminosulfurtrifluoride.
    [0017] The removal of protecting groups is carried out in conventional manner as is the isolation and purification of the products obtained.
    [0018] The preparation and interconversion of ester, protected and salt forms is also carried out in conventional manner. Processes for preparing carbapenems in their various forms are also described in the literature for example in European Patent Application Publications 1628, 10316, 17992, 37080, 37081, 388869, 50334, 33209, 44142, 60612, 61231, 44170, 59478, 58317 and can where appropriate be employed analogously for preparing compounds according to the invention.
    [0019] The starting materials of formula III are new and can be prepared by introducing the group R8 into a compound of formula V
    [0020]
    wherein R1 , R3 and R8 are as defi ned above.
    [0021] Examples of leaving groups R8 are those formed by reacti on of the hydroxy group wi th a phosphori caci dester Chl ori de e. g. wi th phosphori c aci d dipheny lester Chlori de or wi th a sul phoni c aci d e. g. wi th p-tol uene sulphoni c aci d.
    [0022] The coxpounds of formula IV can be prepared analogously to process A) above from compounds of formul a Va
    [0023]
    [0024] The process is conventional and ccmpriscs introduction of the group R8 followed by group -S-R2.
    [0025] The compounds of formula V are also new and can be prepared for example according to the following reaction schemes or analogously to methods described in the above mentioned reaction schemes.


    The reactions shown in these schemes can be carried out using procedures conventional for the type of reaction involved. Cyclisation can for example be carried out in an inert solvent such as an aromatic hydrocarbon e.g. benzene in the presence of a transitional metal catalyst. Examples of a transitional metal catalyst are rhodium(II)-acetate or copper acetylacetonate.
    [0026] The compounds of formula V and Va can exist in the following tautomeric forms
    [0027]
    [0028] The remaining intermediates are either known or can be prepared analogously to known methods and/or as described hereinafter in the examples.
    [0029] Carbapenems such as those of the present application contain 2 centres of chirality in the ring (5 and 6)
    [0030]
    [0031] They can be present in the various configurations ae 6R,5R-, 6S,5S-, 6S,5R- or 6R,5S-isomers or as mixtures thereof. When the starting materials employed are in a particular configuration the end products obtained will have the same configuration and mixed starting materials will produce mixed end products. The configuration of these compounds thus does not alter during reactions such as A) or B) above. Mixtures of isomers can be separated by conventional methods such as fractional crystallisation.
    [0032] It is known tnat the biological activity can be attributed to compounds, whsrein the 5-position is in R-configuration. A further centre of chirality is present when R1 is hydrogen and this also remains unaffected during reactions such as A) above. In reactions such as B), however, where fluorine is introduced Inversion occurs. Thus fiuorination of an 8-R-hydroxy starting material will yield an 8-S-fluoro end product and vice-versa.
    [0033] The compounds of formula I in free form or easily cleavable ester form exhibit chemotherapeutic, in particular anti-microbial activity as indicated by their inhibiting effect against various bacteria, e.g. Pseudomonas aeroginosa, Enterobacter cloacae, Enterobacter agglomerans, Staphylococcus epidermidis, Streptococcus aronson, Streptococcus pneumoniae, Aerococcus viridans, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus faecalis, Escherichia coli, Proteus vulgaris, Proteus mirabilis, Proteus morganii, Klebsiella pneumoniae, Serratia marcescens and Salmonella typhimurium in vitro in series dilution tests at concentrations of, for example, 0.001 to 50 ug/ml, and in vivo in the mouse at dosages of, for example, about 0.1 to 100mg/kg of animal body weight.
    [0034] The compounds also exhibit an inhibiting effect against ß-lactamases at concentration between 0.1 and 10 ug/ml. The enzymatic activity of β-lactamase-preparations of gram-positive and gram-negative bacteria may be tested using the chromogenic Substrate Nitrocefin (Lit: C.H. O'Callaghan et.al., Novel method for detection of ß-lactamases by using a chromogenic cephalosporin Substrate; Antimicrobial Agents and Chemotherapy, Vol. 1, No. 4, 283-288/1972). The inhibition of ß-lactamase is tested in 0.1 M phosphatebuffer (pH = 7.0) using the same Substrate. The enzymes are preincubated together with the inhibitors at appropriate concentrations at 25°C or the inhibitors and the Substrate (Nitrocefin) are added simultaneously and the inhibition of substratehydrolysis caused by the inhibitors in comparison to the noninhibited hydrolysis is measured. The activity is expressed in % inhibition or in IC50(=concentration of inhibitor, which inhibits 50% of the enzyme). This inhibi ting effect is also noticeable in the marked synergism demonstrated with other ß-lactam antibiotics against ß-lactamase producing bacteria. The compounds of the present invention are stable to ß-lactamases.
    [0035] The compounds are therefore ϊndicated for use as chemotherapeutics in particular as antibacterial ly active antibiotics.
    [0036] For this use a suitable total daily dose is from about 1 to 6 g sui tably given two to four times dai ly at dosages of about 250 to 3000 mg or in retard form.
    [0037] Compounds which contain a free salt forming group can be employed in this form or in the form of a chemotherapeutically acceptable salt thereof, which forms have the same order of activity as the free forms. Suitable salt forms include alkali and alkaline earth metal and ammonium or amino acid salt forms.
    [0038] Compounds may be admixed with conventional chemotherapeutically acceptable diluents and carriers, and administered in such forms as tablets or capsules or parenterally. Such compositions also form part of the invention.
    [0039] The invention therefore also concerns a method of combating bacteria comprising administering to a subject in need of such treatment an effective amount of a compound of formula I or a chemotherapeutically acceptable salt. thereof and such compounds for use as chemotherapeutic agents, in particular anti-bacterially active antibiotics.
    [0040] Lower alkyl moieties contain 1 to 6 (e.g. 1-4) esp. 1 or 2 carbon atoms. Correspondingly alkenyl and alkynyl moieties contain 2 to 4 particularly 2 or 3 carbon atoms. Cycloalkyl groups contain preferably 3 to 6 carbon atoms.
    [0041] By lower acylaminoalkyl is to be understood e.g. -CH2CH2.NH.C0.C2H5- -CH3; -CH2CH2;NH.CO.CH2.C6H5; -CH2CH2.NH.C0.CH2CH2.NH2; -CH2CH2.NH.CO.CH2.NH2. Heterocycles as R7 include e.g.
    [0042]
    and morpholino. Protecting groups are those conventionally employed in antibiotics chemistry to protect OH, NH2 and COOH groups. They include p-nitrobenzyl, p-bitrobenzyloxycarbonyl, t-butyl-dimethylsilyl, trimethylsilyl.
    [0043] Physiologically hydrolysable- and acceptable-ester groups (also known as easily cleavable ester groups) are those which are hydrolysable under physiological conditions toyieldbases which are themselves physiologically acceptable, such esters include acetoxymethyl, 1-acetoxyethyl, 1-ethoxycarbonyloxyethyl, 5-indanyl or preferably, pivaloyloxymethyl, hexanoyloxymethyl , phthalidyl, ethoxycarbonylmethoxymethyl or 3-ethoxycarbonyl-1-acetonyl.
    [0044] It will be appreciated that certain protecting groups can also be physiologically hydrolysable- and acceptable- groups and vice versa.
    [0045] Preferred substituents are R1 = a) H; b) CH3 R2 = a) lower alkyl optionally mono- or di-substituted by amino, mono- or di-lower alkylamino, acylamino, carboxy; b) -(CH2)p-R7 c) II, Ila or Ilb preferably Ila
    [0046] R4,R5,R6 = a) H, Alkyl especially methyl b) closed rings R7 = a) individual heterocycles as listed above b) methyl tetrazolyl , morpholinyl p = 0, 1, 2, 3 preferably 0 or 2 m = 2 or 3 preferably 2 n = 1, 2, or 3 preferably 1
    [0047] Combinations of these meanings and the preferrcd forms thereof are especially interesting. Examples are R1 = hydrogen or methyl; R2 = lower alkyl, optionally mono- or disubstituted by amino, alkylamino, dialkylamino, acylamino, carboxy, imino, alkylimino and/or a heterocycle, e.g. methyltetrazolyl or morpholinyl. Examples of particular compound groups of formula I are those wherein R1 represents hydrogen and R2 represents hydrogen, lower alkyl, lower alkenyl, cycloalkyl which may be substituted. by amino, mono- or di-(lower)- alkylamino, lower acylamino, carboxy, lower alkoxy carbonyl or carbamoyl whereby when a cycloalkyl group is substituted by amino or mono- or di- (lower)-alkylamino the nitrogen thereof may form part of the ring; or a group of formula II or Ila, wherein R4 , R5 and R6 may be the same or different and represent hydrogen or lower alkyl and m and n are as defined above and the carboxy group at position two is in free form or in protected or easily cleavable ester form or in the form of a salt with an organic or inorganic cation. ( Compound Group P1 (2))
    [0048] A further group is that wherein
    [0049] R1 represents hydrogen or methyl, R2 represents hydrogen, lower alkyl, lower alkenyl, cycloalkyl which may be substituted by amino, mono- or di-(lower)- alkylamino, lower acylamino, carboxy, lewer alkoxy carbonyl or carbamoyl whereby when a cycloalkyl group is substituted by amino or mono- er di- (lower)-alkylamino the nitrogen thereof may form part of the ring; a group of formula -(CH2)p -R7 wherein p represents 0, 1, 2 or 3 and R7 represents phenyl or a 5- or 6-membered. saturated or unsaturated heterocycle containing one or more heteroatoms selected from O, S and/or N: or a group of formula II or Ila wherein R4, R5 and R6 may be the same or different and represent hydrogen or lower alkyl and rn and n are as defined above and the carboxy group at position two is in free form or in protected or easily cleavable ester form or in the form of a salt with an organic or inorganic cation. (Compound Group P3)
    [0050] Particularly preferred Single compounds are (5RS,6RS)-1-aza-6-(1(RS)-fluorethyl )-3-(N-dimethyl-N'-methylamidinomethylthio)-7-oxobicyclo [3.2.0]hept-2-ene-2-carboxylic acid and (5R3,6RS)-1-aza-6-(1-(RS)- fluorethyl)-3-(N-dimethyl-amidinomethylthio]-7-oxobicyclo [3.2.0]heμt-2- ene-2-carboxylic acid. The following examples illustrate the invention whereby temperatures are expressed in degrees centigrade.
    [0051] Example 1 : (5RS,6RS)-1-aza-6-[1(RS)-fTuorethyl]-3-(2-(4-nitrobenzyl- oxycarbonyl)aminoethylthio]-7-oxobicyclo[3.2.0]heρt-2-ene-2-carboxylic acid.4-nitrobenzylester (process a):
    [0052] To an ice-cold solution of 90mg of (5RS,6RS)-1-aza-3,7-dioxo-6-[1(RS)- fluorethyl]-bicyclo[3.2.0]heptane-2-carboxylic acid.4-nitrobenzylester in 20 ml abs. acetonitrile are added 0.06 ml of diisopropylamine followed by 0.06 ml of phosphoric acid di phenyl ester Chloride. After 15 minutes at 0° a further 0.06 ml of diisopropylamine are added followed by 73 mg of 4-nitrobenzyloxycarbonylcysteamine in 5 ml abs. acetonitrile. Stirring is continued for 1 hour at 0° and the reaction mixture then partitioned between ethyl acetate and saturated aqueous NaCl . After drying over MgSO4 the organic phase is evaporated to dryness and the residue chromatographed over silica gel (eluant:ethylacetate/diisopropylether= 9/1).
    [0053] NMR (CDCl3): 1.52(dd, 3, J = 25, 6 Hz); 2.7-3.6 (m,7); 4.26 (tm, 1 , J = 7 Hz);4.98 (dq, 1, J = 48, 7 Hz); 5.22 (s, 2); 5.26 (d, 1 , J = 13.5 Hz);
    [0054] 5.52 (d, 1, J = 13.5 Hz); 7.53 (d, 2, J = 9Hz); 7.68 (d, 2,J = 9 Hz); 8.25
    [0055] (d, 4, J = 9 Hz).
    [0056] Removal of the protecting groups to prepare (5RS,6RS)-3-(2-aminoethylthio)-1-aza-6-[1(RS)-fluorethyl]-7-oxobicyclo[3.2.0]hept-2-ene-2-carboxylic acid can be carried out as follows:
    [0057] A suspension of 50 mg of (5RS,6RS)-1-aza-6-[1(RS)-fluorethyl]-3-[2-(4-nitrobenzyloxycarbonyl)amirιoethylthio]-7-oxobicyclor3.2.0]hept-2-ene-2-carboxylic acid.4-nitrobenzylester and 50 mg of 10% Pd/C in 20 ml of tetrahydrofuran and 10 ml water are hydrogenaced at room temperature and 3 bar hydrogen pressure for 30 minutes in the presence of 5 ml of 0.5 M 3-morpholinopropanesulphonic acid-buffer solution (pH 7). After filtrstion of the catalyst and washing of the residue with water the combined filtrates are extracted with ethyl acetate and the aqueous phase freeze-dried. This lyophilisate is purified by chromatography over XAD 2 (eluant:water). Fractions with UV-extinction at 300 nm are combined and Tyophilised to give the title product. UV (pH 7-buffer): λmax = 295 nm (ε = 8000).
    [0058] Example 2: (5RS, 6RS)-3-(2-acetylaminoethylthio)-1-aza-6-(1-fluoro-1-methyl- ethyl)-7-oxobicyclo[3.2.0]hept-2-ene-2-carboxylic acid.4-nitro benzylester (Process a):
    [0059] To an ice-cold solution of 150 mg of (5RS,6RS)-1-aza-3,7-dioxo-6-(1-fluoro- 1-methylethyl)bicyclo[3.2.0]heptane-2-carboxylic acid.4-nitrobenzyl ester in 10 ml abs. acetonitrile are added 0.11 ml of N-ethyl diisopropylamine followed by 0.13 ml of phosphoric acid diphenylester chloride. After 15 min at 0° a further 0.22 ml of N-ethyl diisopropylamine are added followed by 70 mg of N-acetylcysteamine in 5 ml abs. acetonitrile. Stirring is continued at 0° for 1 hour and the residue then partitioned between ethylacetete and saturated aqueous NaCl . The organic phase is dried over MgSO4 and then evaporated to dryness. The residue is chromatographed over silica gel (ethyl acetate/acetone=7/3).
    [0060] Example 3: (5RS, 6RS)-3-(2-acetyl aminoethylthio)-1-aza-6-(1-fluoro-1-methylethyl )-7-oxobicyclo[3.2.0]hept-2-ene-2-carboxylic acid.4-nitroberzylester (Process b):
    [0061] To a -78° cooled solution of 0.12ml of diethylaminosulphurtrifluoride and 75 mg of potassium fluoride in 5 ml abs. dichloromethane is added a solution of 150 mg of (5RS,6SR)-3-(2-acetylaminoethylthio)-1-aza-6-(1-hydroxy-1-methylethyl)-7-oxobicyclo[3.2.0]hept-2-ene-2-carboxylic acid.4-nitrobenzylester in 5 ml abs. dichloromethane. The mixture is stirred for 15 min. at -78° and then mixed with water. After the addition of further dichloromethane the phases are separated and the organic phase washed with saturated NaCl solution, dried over MgSO4 and evaporated to dryness. Chromatography of the residue on silica gel (ethyl acetate/acetone =7/3) yϊelds the title compound m.p. 206-210°.
    [0062] Analogously to these examples or as otherwise hereinbefore described, the following compounds of formula I may be prepared.

    [0063] Example 23: (5R,6P-)-3-(2-acetylaminoethylthio)-1-aza--6-[1(S)—fluor ethy1]-7-oxobicyclo[3.2.0]hept-2-ene-2-carboxylicacid.4-nitrobenzylester
    [0064] Analogously to Example 1.
    [0065] Example 24: (5R,6R)-3-(2-acetylaminoethylthio)-1-aza-[1(S)—fluor ethyl 3-7-oxobicyclo[3.2.0]hept-2-ene-carboxy!ic acid. Na-salt :
    [0066] Analogously to Example 1. λ max =298.
    [0067] Example 25: (+)-(5R,6R)-1-aza-6-[1(R)-flυorethyl]-3-(2S)-[2-(4-nitrobenzyloxy carbonyl )aminoethylthio]-7-oxobicyclo[3.2.0]hept-3-ene-2-carboxylic acid.4- nitrobenzyl ester:
    [0068] 0.506 ml of diisopropyl ethylamine and 0.486 ml of diphenylphosphoric acid ester chloride are added at -30° and with stirring to a solution of 680.4 mg of (5R,6R)-3,7-dicxo-6-(1-fluorethyl)-1-azabicyclo[3.2.0]heptane- 2-carboxylic acid.4-nitrobenzylester in 20 ml of dimethylformamide. The reaction mixture is left standing for 30 minutes at -30° and then mixed with 0.404 m! of diisopropylamine. A solution of 1.016 g of N-(4-nitrobenzy loxycarbonyl)-D-cysteine.4-nitrobenzylester in 4 ml of abs. dimethyl formamide is then added dropwise, the mixture stirred for 30 mintues at -30° and then diluted with 200 ml of dichloromethane. The organic solution is washed successively with 140 ml each of 0.1M phosphate buffer of pH 8.4,
    [0069] 6.9 and 8.4 and dried with Na2SO4. This solution can be used for preparation of the optical isomers. [The racemate can be obtained by filtering the dichloromethane solution concentrating under vacuυm to ca. 20 ml and chromatographing the residue on silica gel (benzene/ethylacetate = 3/1). The fractions with UV Rf of 0.30 (benzene/ethylacetate = 2/1) are collected and dried]
    [0070] For preparation of the isomer the dichloromethane solution is evaporated to dryness, the residue washed with 20ml of chloroform and dried. The filtrate is evaporated to a sirup and then chromatographed over silica gel (eluant: benzene/ethylacetate = 3/1). The fractions are combined and evaporated under reduced pressure to dryness. The residue is treated with 5 ml of chloroform, filtered and washed with 10 ml of chloroform. A weakly yellow, amorphous powder is obtained [α]D2 3= +27.9° (c=0.5 in dichloromethane). For further purification this powder is dissolved in 20 ml of dichloromethane and filtered. The filtrate is concentrated to ca. 1 ml and then treated with 1 - 2 ml of chloroform to give a weakly yellow, amorphous powder [α]D 23= +29° (c=0.5 in dichloromethane).
    [0071] NMR- SPECTRA
    [0072] Example: Spectrum:
    [0073] 2,3 1.49 (d, 3, J = 20 Hz);.1.57 (d, 3, J = 20 Hz); 2.00 (s, 3); 2.87-
    [0074] (CDCl3) 3.53 (m, 7); 4.32 (td, 1, J = 10 Hz, 2.7); 5.25 (d, 1, J = 13.7 Hz); 5.52 (d, 1, J = 13.7 Hz); 5.89 (br, 1); 7.67 (d, 2, J = 8 Hz); 8.24 (d, 2, J = 8 Hz).
    [0075] 4 1.52 (dd, 3, J = 25 and 6 Hz); 2.7-5.6 (m, 7); 4.26 (tm, 1, J =
    [0076] (CDCl3) 7 Hz); 4.98 (dq, 1, J = 48 and 7 Hz); 5.22 (s, 2); 5.26 (d, 1, J =
    [0077] 13.5 Hz); 5.52 (d, 1, J = 13.5 Hz); 7.53 (d, 2, J = 9 Hz): 7.68
    [0078] (d, 2, J = 9 Hz); 8.25 (d, 4, J = 9 Hz).
    [0079] 5 1.68 (d, 3, J = 22.5 Hz); 1.74 (d, 3, 3 = 22.5 Hz); 2.00 (s. 3);
    [0080] (D2O) 2.85-3.14 (m, 2): 3.16 (dd, 1, 3 = 17.5 and 9 Hz); 3.23 (ad, 1, 3 = 17.5 and 9.5 Hz); 3.42 (t, 2, J = 6.5 Hz); 3.65 (dd, 1 , J = 17.5 and 9.5 Hz); 3.42 (t, 2, J = 6.5 Hz); 3.65 (dd, 1. 3 = 26.5 and 2.5 Hz); 4.27 (td, 1, 3 = 9.5 and 2.5 Hz).
    [0081] 6 1.42 (dd, 3, J = 24 and 7 Hz); 2.45 (t, 4, J = 4.5 Hz); 2.60 (t,
    [0082] (CDCl3/ 2, J = 7.5 Hz); 2.94-3.10 (m, 2); 3.30-3.45 (m, 2); 3.60 (t, 4, DMSO-d6) J = 4.5 Hz); 3.66 (ddd. 1, J = 25, 6 and 2.5 Hz); 4.23 (td, 1, 3 = 9 and 2.5 Hz); 5.03 (dq, 1, 0 = 49 and 6 Hz); 5.27 (d, 1, 3 = 14 Hz); 5.45 (d, 1, J = 14 Hz); 6.98 (br, 1); 7.72 (d, 2, J = 9.5 Hz); 8.20 (d, 2, J = 9.5 Hz).
    [0083] 7 1.58 (dd, 3, J = 25 and 6.5 Hz): 3.06-3.76 (m, 11); 4.02-4.12
    [0084] (D2O) (m, 4); 4.48 (td, 1, J = 9 and 3 Hz); 5.28 (dm, 1, J = 52 Hz).
    [0085] 8 1.43 (dd, 3, 3 = 26 and 6.5 Hz): 2.59 (s, 3); 2.93 (dd, 1, J = 18
    [0086] (D2O) and 9 Hz); 3.02 (dd, 1, J = 18 and 9.5 Hz); 3.56 (ddd, 1, J = 27, 5 and 2.8 Hz); 4.09 (td, 1, J = 9.5 and 2.8 Hz); 5.12 (dm, 1, J = 48 Hz). 10 1.45 (dd, 3, J = 25 and 6.5 Hz); 2.90-3.03 (m, 12); 3.07-3.57 (D2O) (m, 6); 3.67 (ddd, 1, J = 28, 5 and 2.5 Hz); 4.29 (td, 1, J = 9 and 2.5 Hz); 5.14 (dm, 1, J = 49 Hz).
    [0087] 11 1.41 (dd, 3, J = 6 and 25 Hz); 2.80-3.65 (m, 5); 3.75-3.97 (m, (D2O) 1); 4.29 (dt, 1, J = 2.5 and 8.5 Hz); 5.11 (m, 1, J = 6, 7.5 and 48.8 Hz);
    [0088] 12 1.46 (dd, 3, J = 24 and 7 Hz); 3.10-3.57 (m, 11); 3.63 (ddd, 1,
    [0089] (CDCl3/ J = 24, 6 and 2.5 Hz); 4.15 (d, 1. J = 12.5 Hz); 4.27 (d, 1, J =
    [0090] DMSO-d6) 12.5 Hz); 4.33 (td, 1. J = 9 and 2.5 Hz); 5.05 (dm, 1, J = 49 Hz); 5.29 (d, 1, J = 14 Hz); 5.51 (d, 1, J = 14 Hz); 7.70 (d, 2, J = 9 Hz); 8.28 (d, 2, J = 9 Hz); 8.90 (br, 1).
    [0091] 13 1.46 (dd, 3, J = 25 and 6.5 Hz); 3.12 (s, 3); 3.15 (s, 3); 3.25 (D2O) (dd, 1, J = 18 and 9 Hz); 3.32 (dd, 1 , J = 38 and 10 Hz); 3.36 (s, 3); 3.71 (ddd, 1, J = 27, 5 and 2.8 Hz); 4.01 (d, 1, J = 12.5 Hz); 4.09 (d, 1, J = 12.5 Hz); 4.35 (td, 1, J = 9.5 and 2.8 Hz); 5.25 (dm, 1, J = 49 Hz).
    [0092] 14 1.44 (dd, 1, J = 25 and 6.5 Hz); 3.14 (d, 2, J = 9.5 Hz); 3.17 (D2O) (s, 3); 3.30 (s, 3); 3.71 (ddd, 1, J = 28, 5 and 2.5 Hz); 4.00 (s, 2); 4.31 (td, 1, J = 9.5 and 2.5 Hz); 5.15 (dm, 1, 3 = 49 Hz).
    [0093] 16 0.70-1.05 (m, 3); 1.22-1.60 (rn, 6); 1.52 (dd, 3, 3 = 25 and (CDCI3) 7 Hz); 2.67-3.00 (m, 2); 3.02-3.54 (m, 3): 4.23 (dd, 1, J = 9.5 and 2.5 Hz); 5.02 (dm, 1, J = 49 Hz); 5.26 (d, 1, 3 = 12.5 Hz); 5.52 (d, 1, J = 12.5 Hz); 7.68 (d, 2, J = 9 Hz); 8.26 (d, 2, J = 9 Hz).
    [0094] 17 0.8-1.02 (m, 3); 1.20-1.56 (m, 6); 1.51 (d, 3, 3 = 21.5 Hz);
    [0095] (CDCl3) 1.58 (d, 3, J = 21.5 Hz); 2.86 (t, 2, J = 7 Hz); 3.11 (dd, 1, J = 16 and 7 Hz); 3.33 (dd, 1, J = 16 and 8 Hz); 3.39 (dd, 1 , J = 18 and 3 Hz); 4.32 (dt, 1, J = 8 and 3 Hz); 5.27 (d, 1, J = 14 Hz); 5.55 (d, 1, 3 = 14 Hz); 7.70 (d, 2, 3 = 9 Hz); 8.26 (d, 2, 3 9 Hz).
    [0096] 18 1.51 (dd, 3, J = 24.5 and 7 Hz); 2.0-2.4 (m, 2); 2.64-3.04 (m, (CDCl3) 1); 3.10-3.90 (m, 5); 4.0-4.9 (m, 2.5); 5.1-5.64 (m, 6.5); 7.34- 7.67 (m, 6); 8.04-8.36 (m, 6).
    [0097] 19 1.20-1.37 (m, 3); 1.50 (dd, 3, J = 24 and 3 Hz); 2.62-3.56 (m,
    [0098] (CDCl3) 6); 3.95-4.30 (m, 1); 4.80-5.32 (m, 1); 5 .22 (s. 2); 5.23 (d, 1, 3 = 14.5 Hz); 5.54 (d, 1, J = 14.5 Hz); 7.52 (d, 2, J = 9 Hz); 7.70 (d, 2, J = 9 Hz); 8.26 (d, 4, J = 9 Hz).
    [0099] 20 1.48 (d, 3, J = 21.5 Hz); 1.56 (d, 3, J = 21.5 Hz); 2.56 (s, 3); (CDCl3) 2.70-3.53 (m, 5); 4.25 (td, 1, J = 9.5 and 2.5 Hz); 4.51 (t, 2, 3 = 7 Hz); 5.28 (d, 1, J = 13.5 Hz); 5.52 (d, 1, J = 13.5 Hz); 7.68 (d, 2, J = 9 Hz); 8.28 (d, 2, J = 9 Hz).
    [0100] 21 1.50 (dd, 3, J = 24.5 and 6.5 Hz): 2.56 (s, 3); 2.74-3.56 (m, 5): (CDCl3) 4.24 (td, 1, J = 9 and 2.5 Hz); 4.30-4.60 (m, 2); 5.02 (dm, 1, J = 49 Hz); 5.27 (d, 1, J = 14.5 Hz); 5.49 (d, 1, J = 14.5 Hz); 7.67 (d. 2, J = 9 Hz); 8.27 (d, 2, J = 9 Hz).
    [0101] 22 1.45 (dd, 3, J = 24 and 6.5 Hz); 3.11 (e, 3); 3.23 (s, 3); 3.30-
    [0102] (CDCl3/ 3.60 (m, 2.), 3.71 (ddd, 1, J = 25, 5.5 and 2.5 Hz); 4.26 (s, 2);
    [0103] DMSO-d6 4.30 (td. 1, J = 10 and 2.5 Hz); 5.04 (dm, 1, J = 48 Hz); 5.30 (d, 1, J = 15 Hz); 5.50 (d, 1, J = 15 Hz); 7.72 (d, 2, J = 9 Hz); 8.25 (d, 2, J = 9 Hz); 9.03 (br, 1): 9.75 (br, 1).
    [0104] 23 1.57 (dd. 3, J = 23.5 and 6.3 Hz); 2.0 (s, 3); 2.87-3.74 (m, 7);
    [0105] (CDCl3/ 4.34 (td, 1, J = 9 and 2.7 Hz); 5.02 (dm, 1, J = 49 Hz); 5.30 Ac eton-d6) (d, 1, J = 16 Hz); 5.55 (d, 1, 0 = 16 Hz); 6.78 (br, 1); 7.72 (d, 2, J = 9 Hz); 8.28 (d, 2, J = 9 Hz).
    [0106] The requi red starti ng materi als can be prepared as fol l ows : A) (5RS,6RS)-1-aza-3,7-dioxo-6-[1(RS)-fluorethyl]-bicyclo[3.2.0]heptane- 2-carboxylic acid.4-nitrobenzylester (for examples 4, 6-8, 10-16, 18, 19, 21): [reaction scheme 1 steps g) to k)] a) ( 3RS , 4RS )-3-[1(RS)-fluorethyl]-2-oxoazetidine-4-yl-acetic acid benzyl ester
    [0107] To a -78° cooled solution of 1.5 ml of diethylaminosulphurtrifluoride in 4 ml abs. dichloromethane is added a solution of 2.52 g of (3SR,4RS)-3-[l(SR)-hydroxyethyl]-2-oxoazetidine-4-yl-acetic acid benzyl ester (prepared analogously to D.G. Melillo et.al., Tetrahedron Letters 21 , 2783 [1980]) in 4 ml abs. dichloromethane. The mixture is stirred for 5 minutes at -78° and mixed with excess cold saturated NaHCO3. After addition of further dichloromethane the phases are separated, the organic phase dried over magnesium sulphate and evaporated to dryness. Chromatography of the residue over silica gal (cyclohexane/ethyl acetate = 2/1) yields the title compound m.p. -40-43°.
    [0108] IR (CHCl3): 1765, 1730 cm-1
    [0109] NMR (CDCI3): 1.45 (dd, 3, J = 24, 6.5 Hz); 2.68 (dd, 1, J = 16, 9 Hz); 2.86 (dd, 1, J = 16, 5.5 Hz); 3.01 (ddd, 1, J = 18.5, 7, 2.5 Hz); 4.02 (ddd, 1, J= 9, 5.5, 2.5 Hz); 4.97 (dq, 1,J = 48, 6.5 Hz); 5.18 (s, 2); 6.25 (br, 1); 7.40 (s, 5).
    [0110] b) (3RS,4RS)-3-[1(RS)-fluorethyl]-2-oxoazetidire-4-yl-acetic acid
    [0111] A mixture of 700 mg of the corresponding benzylester and 50 mg of 10% Pd/C in 50 ml of ethanol is hydrogenated at a hydrogen pressure of 10 bars for 30 mins. Filtration and concentration of the filtrate to dryness yields the title compound m.p. 137-141°.
    [0112] IR (KBr): 3317, 2983, 2923, 2577, 3720 cm-1
    [0113] NMR (CDCl3/CO3OD): 1.45 (dd, 3, J = 23.5, 6.5 Hz); 2.62 (dd, 2, J= 16, 9 Hz); 2.8C (dd, 1, J = 16, 4.5 Hz); 3.01 (ddd, 1, J = 21, 6.5, 2.5 Hz); 4.00 (ddd, 1,J = 9, 4.5, 2.5 Hz); 4.93 (dq, 1,J = 49.5, 6.5 Hz). c)[(3RS,4RS)-3-[1(RS)-fluorethyl]-2-oxoazetidine-4-yl]-(2-oxo)butyric-acid.4-nitrobenzylester
    [0114] A solution of 352 mg of (3RS,4RS)-3-[1(RS)-fluorethyl]-2-oxo-azetidine-4-yl-acetic acid in 15 ml abs. tetrahydrofuran is stirred for 5 hours at room temperature with 359 mg of carbonyl diimidazole. At the same time a solution of 995 mg of malonic acid mono-4-nitrobenzylester in 15 ml abs. tetrahydrofuran is mixed with 253 mg of magnesium ethanolate and stirred for 1 hour at room temperature. The two Solutions are combined and stirred for 16 hours at room temperature. The mixture is diluted with ether and washed with 0.1 N KCl. The aqueous phase is extracted once more with ethylacetate and the combined extracts dried over MgSO4 and evaporated to dryness. Chromatography of the residue of silica gel (ethylacetate) yields the title compound m.p. 115-118°.
    [0115] IR (CH2Cl2): 3407, 2928, 1770, 1720, 1525, 1350 cm-1
    [0116] NMR (CDCl3): 1.47 (dd, 3, J = 18, 7 Hz); 2.86 (dd, 1, J = 18.5, 10 Hz); 2.94 (ddd, 1. J = 18, 7, 2 Hz); 3.09 (dd, 1,J = 18.5, 4 Hz); 3.53 (s, 2); 4.00 (ddd, J, J = 10, 4, 2 Hz); 4.93 (dq, 1,J= 48, 7 Hz); 5.28 (s, 2); 6.18 (br, 1); 7.52 (d, 2, J = 9 Hz); 8.26 (d> 2, 3 = 9 Hz).
    [0117] d)[(3R5,4RS)-3-[1(RS)-fluorethyl]-2-oxoazetidine-4-yl]-(2-oxo-3--diazo)- butyric—acid.4-nitrobenzylester
    [0118] To an ice-ccoled solution of 459 mg of (3RS,4RS)-3-[l(RS)-fluorethyl]- 2-oxoazetidine-4-yl-(2-oxo)butyric--acid.4-nitrobenzylester and 374 mg of 4-carboxybenzenesulfonylazide in 15 ml of ethylacetate are added in one lot 0.67 ml of triethylamine. After removal of the cooling bath stirring is continued at room temperature during which time a precipitate forms. This is filtered off and the filtrate washed once with saturated NaHCO3 and dried over MgSO4. Removal of the solvent yields the title compound m.p. 138-141°.
    [0119] IR (KBr):3414, 3204, 2135, 1760, 1720, 1650, 1520 cm-1 NMR (CDCl3): 1.45 (dd, 3, J = 23.5, 7 Hz); 3.04 (ddd, 1, J = 19, 7, 2 Hz); 3.06 Cdd, 1, J = 18, 10 Hz); 3.44 (dd, 1, J = 18, 4 Hz); 4.04 (ddd, 1,J = 10, 4, 2 Hz); 4.98 (dq, 1, J = 48, 7 Hz); 5.38 (s, 2); 6.17 (br, 1); 7.58 (d, 2, J = 9 Hz); 8.31 (d, 2, J = 9 Hz). e) (5RS,6RS)-1-aza-3,7-dioxo-6-[1(RS)-fluorethyl]-bicyclo[3.2.0]heptane- 2-carboxylic acid.4-nitrobenzyl ester
    [0120] A suspension of (3RS,4RS)-3-[1(RS)-fluorethyl]-2-oxoazetidine-4-yl-(2- oxo-3-diazo)butyric—acid.4-nitrobenzylester and 2 mg of rhodium(II)-acetate in 5 ml abs. benzene is warmed for 5 mins under argon. After cooling to room temperature the catalyst is filtered off and the filtrate evaporated to dryness. The title compound is obtained as a colourless foam resin.
    [0121] IR (CH2Cl2): 1775, 1750, 1525, 1350 cm-1
    [0122] NMR (CDCl3): 1.52 (dd, 3, J - 25, 7 Hz); 2.52 (dd, 1, J = 18.5, 7.5 Hz); 2.96 (dd, 1, J = 18.5, 7 Hz); 3.35 (ddd, 1, J = 13, 8, 2 Hz); 4.20 (td, 1. J = 7, 2 Hz); 4.80 (s, 1); 5.11 (dm, 3 , J = 43 Hz); 5.26 (d, 1,J = 12.5 Hz); 5.37 (d, 1, J = 12.5 Hz); 7.58 (d, 2, J = 9 Hz); 8.29 (d, 2, J = 9 Hz).
    [0123] B) (5RS, 6RS)-1-aza-3,7-dioxo-6-(1-fluoro-1-methylethyl)bicyclo[3.2.0]heptane-2- carboxylic acid.4.nitrobenzylester (for examples 2,5,9, 17 and 20): [(reaction scheme 1 a) to k)] a) 2-oxo-3-trans-(1-hydroxy-1-methylethyl)-4-(2-trimethylsilyldithian-2-yl)- methyl-1-tert.butyldimethylsilylazetidine
    [0124] To a solution of 10.1 g of diisopropylamine in 500 ml of abs. tetra hydrofuran are added at -75°, .75 ml of 1.6 N solution of n-butyllithium in hexane. After 20 mins. at -75°, 20 g of 1-tert.butyldimethyl-2-oxo-4-(2-trimethylsilyldithiane-2-yl)methylazetidine are added followed after 20 mins. by 17 ml abs. acetone. The reaction mixture is diluted with 500 ml saturated NH4Cl and extracted with ethylacetate. Drying and concentration of the extracts yields the title product. NMR (CDCl3): 0.26 (s, 15); 0.9S (s, 9); 1.24 (s, 3); 1.40 (s, 3); 1.80-2.10 (m, 2); 2.34 (d, 1, J = 1 Hz); 2.40 (s, 1); 2.60-3.00 (m, 4); 3.19 (d, 1, J = 2 Hz); 3.80 (s, 1); 3.90 (m, 1).
    [0125] b) trimsthylsilyl-(2-oxo-3-trans-(1-hxdroxy-1-methylethyl)-1-tert.butyldimethyl-silylazetidine-4-yl)methylketone
    [0126] 28 g of 2-oxo-3-trans-(1-hydroxy-1-methylethyl)-4-(2-trimethylsilyldithian-2- yl)-methyl-1-tert.butyldimethylsilylazetidine,23.65 g red mercuric oxide and 43 g of mercuric chloride are refluxed for 1 hour in 400 ml of 95% methanol. After filtration from the mercury salts the filtrate is concentrated and the residue partitioned between ethylacetate and saturated NH4Cl. Drying and concentration of the organic phase yields the title compound as a colourless oil.
    [0127] NMR (CDCl3): 0.22 (s, 6); 0.24 (s, 9); 0.93 (s, 9): 1.30 (s, 3); 1.34 (e, 3); 2.84 (d.1, J = 2 Hz); 2.88 (dd, 1, J = 19 and 10 Hz); 3.2S(dd, 1 , J = 19 and 3.6 Hz); 3.86 (ddd, 1, J = 10, 3.6 and 2 Hz).
    [0128] c) 1-tert-butyldimethylsilyl-2-oxo-3-trans-(1-hydroxy-1-methylethyl)azetidine-4-yl-acetic acid
    [0129] 5 g of trimethylsilyl-(2-oxo-3-trans-(1-hydroxy-1-methylethyl)-1-tert.butyl-dimethylsilylazetidine-4-yl)methylketone are refluxed for 1 hour in 120ml of methanol with 10 ml of 302 hydrogen peroxide. After concentration to dryness the residue is taken up in ethylacetate, extracted twice with 5% aqueous NaHCO3 and the aqueous phase further extracted once with ethylacetate. The aqueous phase is covered with ethylacetate, the pH adjusted to 3.5 with half-concentrated HCl and after separation of the ethylacetate phase again extracted twice with ethylacetate. After drying and removal of the solvent from the combined ethylacetate extracts, the title compound ie obtained as a colourless oil. NMR (CDCl3):0.22(s,3):0.24(s,3);0.96 (s,9);1.32(s,3);1.34(s,3);2.56 (dd,1,J=19 and 10Hz);2.92 (dd,1,J=19 and 3.6 Hz);3.11 (d,1 ,J=2Hz); 3.86 ( ddd, 1, J=10, 3.6 and 2 Hz). d) 1-tert.butyldimethylsilyl-2-oxo-3-(trans)-(1-hydroxy-1-methylethyl)- azetidine-4-yl-acetic acid benzylester
    [0130] 5 g 1-tert.butyldimethylsilyl-2-oxo-3-trans-(1-hydroxy-l-methylethyl)azetidine- 4-yl-acetic acid, 1.71 ml of benzyl alcohol and 300 mg of 4-dimethyl aminopyridine in 30 ml abs. dichloromethane are rapidly mixed with a solution of 4 g of dicyclohexylcarbodiimide and stirred for a further 2 hours at room temperature. After addition of 50 ml of ether and 50 ml of diisopropylether filtration is carried out, the residue carefυlly washed with ether and the filtrate evaporated to dryness. This residue is chromatographed on a small amount of silica gel to obtain the title compound as a colourless oil.
    [0131] NMR (CDCl3): 0.16 (e, 3); 0.18 (s, 3); 0.90 (s, 9); 1.24 (s.3); 1.26 (s, 3); 2.53 (dd, 1,J = 16.2 and10.6 Hz); 2.63 (s.1); 2.82 (dd, 1,J = 16.2 and 4Hz); 3.02 (d, 1, J = 2.7 Hz); 3.33 (ddd, 1, J = 10.6, 4 and 2.7 Hz); 5.10 (s, 2); 7.37 (s,5);
    [0132] e) (3SR,4RS)-3-(1 -hydroxy-1-methylethyl)-2-oxoazetidine-4-yl-acetic- acid benzylester
    [0133] To an ice-cold solution of 3.7 g 1-tert.butyldimethylsilyl-2-oxo-3- (trans)-(1-hydroxy-1-methylethyl)azetidine-4-yl-acetic acid benzylester in 130 ml of methanol/water (9/1) are added 6.6 ml of conc. HCl . This mixture is stirred for 30 minutes at 0° and 31/2 hours at 25°. The solution is concentrated and the residue taken up in ethylacetate, washed once with aq. NaCl, dried over MgSO4 and evaporated to dryness to yield the title compound
    [0134] NMR (CDCl3):1.24 (s,3); 1.34 (s, 3); 2.60-2.84 (m,3); 2.87 (d, 1 , J = 1.8 Hz); 3.94 (ddd, 1, J = 8, 6.3 and 1.8 Hz); 5.13 (s, 2); 5.57 (br, 1); 7.37 (s, 5). f) (3RS,4RS)-3-(1-fluoro-1-methylethyl)-2-oxoazetidine-4-yl-acetic acid benzylester
    [0135] To a -78° cold solution of 3 ml of diethylaminosulphurtrifluoride and
    [0136] 1.7 g of potassium fluoride in 80 ml of dichloromethane is added a solution of 3.2 g of (3SR,4RS)-3-(1-hydroxy-1-methylethyl)-2-oxoazetidine-4-yl acetic acid benzylester in 170 ml of dichloromethane. This mixture is stirred for 15 minutes at -78° and then mixed with water. After addition of further dichloromethane the phases are separated and the organic phase washed with saturated NaCl, dried over MgSO4 and evaporated to dryness. Chromatography of the residue over silica gel (ethylacetate/ cyclohexane = 1/1) yields the title compound m.p. 112-116°.
    [0137] NMR (CDCl3): 1.42 (d, 3, J = 21.5 Hz); 1.52 (d, 3,J = 21.5 Hz); 2.62 (dd, 1, J=16.2 and 9 Hz); 2.34 (dd, 1, J = 16.2 and 4.5 Hz);3.00 (dd, 1, J = 21.5 and 2.7 Hz); 4.01 (ddd, 2, J = 9, 4,5 and 2.7 Hz);5.16 (s, 2); 6.34 (br, 1); 7.39 (s, 5).
    [0138] g) (3RS,4RS)-3-(1-fluoro—1-methylethyl)-2-oxoazetidine-4-yl-acetic acid
    [0139] A mixture of lg of (3RS,4RS)-3-(1-fluoro-1-methylethyl)-2-oxoazetidine-4-yl acetic acid benzyl ester and 0.5 g of 10 % Pd/C in 80 ml of methanol is hydrogenated for 31/2 hours under a hydrogen pressure of 1 bar. Filtration and concentration of the filtrate to dryness yields the title compound m.p. 118-122°.
    [0140] NMR (CDCl3/DMSO-d6): 1.43 (d, 3, J = 21.6 Hz); 1.52 ( d, 3, J = 21.6 Hz); 2.57 (dd, 1, J = 16.2 and 9 Hz);2.72 (dd.1. J = 16.2 and 5.4 Hz);3.00 (dd, 1, J =23.5 and 2.5 Hz); 3.96 (ddd, 1,J = 9, 5.4 and 2.5 Hz). h) [(3RS,4RS)-3-(1-fluoro-1-methylethyl)-2-oxazetidire-4-yl]-(2-oxo)butyric- acid.4-nitrobenzylester
    [0141] 700 mg of (3RS,4RS)-3-(1-fluoro-1-methylethyl)-2-oxoazetidine-4-yl-acetic acid are dissolved in 20 ml of tetrahydrofuran, mixed at -20° with 600 mg of carbonyl diimidazole and stirred for 3 hours at +20°. At the same time 900 mg of malonic acid 4-nitrobenzylester and 420 mg of magnesium ethanolate are suspendod in 20 ml of tetrahydrofuran and stirred for 3 hours at room temperature. The first obtained solution is now added to this second solution and stirred overnight. The mixture is then poured onto ether and extracted with 1N HCl and water. Drying of the organic Phase followed by column chromatography of the residue yields the title compound.
    [0142] NMR (CDCl3): 1.44 (d, 3, J = 21.5 Hz); 1.52 (d, 3, J = 21.5 Hz); 2.86 (dd, 1,
    [0143] J = 18 and 10 Hz);2.98 (dd, 1,J = 20 and 3.5 Hz); 3.05(dd, 1 , J = 18 and 4.5 Hz);3.50 (s, 2); 4.02 (dt, 1, J = 10 and 3.5 Hz);5.30 (s, 2); 6.16 (br, 1); 7.58 (d.2, J -- 9 Hz); 8.23 (d, 2. J = 9 Hz).
    [0144] i) (3RS,4RS)-3-(1-fluoro-1-methylethyl)-2-oxoazetidine-4-yl-(2-oxo-3-diazo)- butyric—acid.4-nitrobenzylester
    [0145] To an ice-cold solution of 0.22 g (3RS,4RS)-3-(1-fluoro-1-methylethyl)-2- oxoazetidire-4-yl-(2-oxo)butyric—acid.4-nitrobenzylester and 0.17 g of 4-carboxybenzenesulphonylazide in 20 ml of acetonitrile are added 0.34 ml of triethylamine. After removal of the cooling bath stirring is continued for 30 mins. at room temperature. The mixture is mixed with 100 ml of ethylacetate, washed with 5% NaHCO3 and then water and dried over MgSO4. Removal of the solvent yields the title compound. j) (5RS, 6RS)-1-aza-3,7-dioxo-6-(1-fluoro-1-methylethyl)bicyclo[3.2.0]heptane- 2-carboxylic acid.4-nitrobenzylester
    [0146] A suspension of 0.19 g of (3RS,4RS)-3-(1-fluoro-1-methylethyl)-2-oxoazetidine-4-yl-(2-oxo-3-diazo)butyric-acid.4-nitrobenzylester and 20 mg rhodium(II)- acetate in 100 ml of benzene are heated for 10 minutes at 80° under argon. After cooling to room temperature the catalyst is filtered off and the filtrate evaporated to dryness to obtain the title compound.
    [0147] C) (5RS,6RS)-1-aza-3,7-dioxo-6-(1-fluoro-1-methylethyl)bicyclo[3.2.0]heptane-2-carboxylic acid.4-nitrobenzylester (for examples 2, 5, 9, 17 and 20): [(reaction scheme 2a), b)ii) to e)ii)]
    [0148] a ) 1-tert.butyldimethylsilyl-2-oxo-3-(trans)-[(1-hydroxy-1-methylethyl)- azetidine-4-yl]-(2-oxo)butyric—acid.4-nitrobenzylester
    [0149] 1.2 g of 1-tert.butyldimethylsilyl-2-oxo-3-trans-(1-hydroxy-1-methylethyl)-azetidine-4-yl-acetic acid are dissolved in 20 ml of tetrahydrofuran, mixed at -20° with 1 g of carbonyldiimidazole and stirred for 3 hours at 20°. At the same time 1.9 g of malonic acid -4-nitrobenzylester and 0.7 g of magnesium ethanolate are suspended in 30 ml of tetrahydrofuran and stirred for 3 hours at room temperature. Further reaction and extraction takes place analogously to B)h).
    [0150] NMR (CDCl3): 0.22 (s, 6); 0.96 (s, 9); 1.32 (s, 6); 2.74 (s, 1): 2.86 (dd, 1, J = 18 and 9 Hz); 2.92 (d, 1, J = 2.7 Hz); 3.14 (dd, 1, J = 10 and 4 Hz); 3.60 (s,2); 3.8S(ddd, 1, J=9,4 and 2.7 Hz); 5.30 (s, 2); 7.54 (d, 2, J = 9 Hz); 8.23 (d, 2, J = 9 Hz). b) 2-oxo-3-(trans)-(1-hydroxy-1-methylethyl)azetidine-4-yl-(2-oxo)butyric- acid.4-nitrobenzylester
    [0151] To an ice-cold solution of 1.4 g of 1-tert.butyldimethylsilyl-2-oxo-3- ( trans )-(1-hydroxy-1-methylethyl)azetidine-4-yl-(2-oxo)butyric-acid.4-nitro benzylester in 50 ml of methanol/water (9/1) are added 2 ml of conc. HCl. This mixture is stirred for 30 minutes at 0° and 51/2 hours at 25°. Working-up is analogous to B)e). NMR (CDCl3): 1.26 (s, 3); 1.35 (s, 3); 2.02 (d, 1, J = 2.7 Hz); 2.86 (dd, 1,J=19 and 8.6 Hz); 3.06 (dd, 1, J=19 and 5 Hz); 3.60 (s, 2); 3.96 (ddd, 1, J = 8.6, 5 and 2.7 Hz) ; 5.28 (e, 2); 6.37 (br, 1); 7.57 (d, 2, J = 9 Hz); 8.27 (d, 2, J = 9 Hz).
    [0152] c) 3-(1-hydroxy-1-methylethyl)-2-oxoazetidine-4-yl-(2-oxo-3-diazo)butyric- acid.4-nitrobenzylester
    [0153] To an ice cold solution of 0.45 g of 2-oxo-3-(trans)-(1-hydroxy-1-methyl ethyl )azetidine-4-yl-(2-oxo)butyric--acid.4-nitrobenzylester and 0.33 g of 4-carboxybenzenesulphonylazide in 30 ml of acetonitrile are added 0.67 ml of triethyl amine. The remaining prccedure is analogous to B)i).
    [0154] NMR (CDCl3): 3.30 (s, 3); 1.33 (s, 3); 2.94 (d, 1,J= 2.2 Hz); 3.08 (dd, 1, J = 18 and 8.8 Hz); 3.37 (dd, 1,J=18 and 5 Hz); 3.93 (ddd, 1,J = 0.8.5 and 2.2 Hz); 5.33 (s, 2); 6.10 (br, 1); 7.56 (d, 2, J = 9 Hz); 8.30 (d, 2,J = 9 Hz).
    [0155] d) (5RS,6SR)-1-aza-3,7-di oxo-6-(1-hydroxy-1-methylethyl)bicyclo[3.2.0]heptane-2-carboxylic acid.4-nitrobenzylester
    [0156] A suspension of 0.4 g of 3-(1-hydroxy-1-methylethyl)-2-oxoazetidine-4-yl(2-oxo-3-diazo)butyric—acid.4-nitrobenzylester and 40 mg of rhodium(II)-acetate in 250 ml of abs. benzere is heated for 10 minutes under argon. The remaining procedure is analogous to B)j).
    [0157] NMR (CDCl3): 1.40 (s, 3); 1.46 (s, 3); 2.49 (dd, 1, J = 19 and 7.6 Hz); 2.92 (dd, 1, J=19 and 7.2 Hz); 3.26 (d, 1, J =-2 Hz); 4.16 (td, 3, J = 7.4 and 2Hz); 4.60 (s, 1); 5.23 (d, 1,J = 13.5 Hz); 5.34 (d, 1,J= 13.5 Hz); 7.46 (d, 2,J = 9 Hz); 8.28 (d, 2,J = 9 Hz). e) (5RS,6RS)-1-aza-3,7-dioxo-6-(1-fluoro-1-methylethyl)bicyclo[3.2.03heptane-2-carboxylic acid.4-nitrobenzylester
    [0158] To a -78° cold solution of 0.3 ml of di ethyl aminosulphurtrifluoride and 170 mg of potassium fluoride in 8 ml of dichloromethane is added a solution of 0.35 g of (5RS,6RS)-1-aza-3,7-dioxo-6-(1-hydroxy-1-methylethyl)-bicyclo[3.2.03-heptane-2-carboxylic acid.4-nitrobenzylester in 17 ml of abs. dichloromethane. The mixture is stirred for 15 minutes at -78° and then mixed with water. The remaining procedure is analogous to B)f). m.p. 132-135°.
    [0159] NMR (CDCl3): 1.51 (d, 3, J = 21 Hz); 1.53 (d, 3, J = 21 Hz); 2.56 (dd, 1, J = 18.4 and 7.5 Hz):2.84 (dd, 1, J = 18 and 6.7 Hz); 3.36 (dd, 1, J = 21 and 2.2 Hz); 4.07-4.31 (m, 1); 4.78 (s, 1); 5.26 (d, 1, J = 9.5 Hz); 5.40 (d, 1, J = 9.5 Hz); 7.58 (d, 2, J = 9 Hz); 8.23 (d, 2, J = 9 Hz)
    [0160] D)[ ( 3RS ,4RS )-3- (1-fluoro-1-methylethyl)-2-oxoazmtidine-4-y1]-(2-oxo)butyric-acid.4-nitrobenzylester (reaction scheme 2, b)i), c)i)
    [0161] a) (3RS,4RS)-1-tert.butyldimethylsilyl-3-(1-fluoro-1-methylethyl)-2-oxo-azetidine-4-yl-(2-oxo)butyric-acid.4-nitrobenzvlester To a -78° cold solution of 14.4 ml of dimethylaminosulphurtrifluoride and 18 g of potassium fluoride in 500 ml of dichloromethane is added a solution of 18 g of (3SR,4RS)-1-tert.butyldimethylsilyl-3-(1-hydroxy-1-methylethyl)—2-oxoazetidine-4-yl-(2-oxo)butyric—acid.4-nitrobenzy!ester in 400 ml of dichloromethane. Further procedure is as Bf) (eluant dichloromethane/ethyl acetate = 20/1).
    [0162] IR(CH2Cl2):1740,1520 cm-1. b ) [( 3RS , 4RS )-3- (1-fluoro-1-methylethyl)-2-oxoazetidine-4-yl]-(2-oxo)butyric- acid.4-nitrobenzylester
    [0163] To an ice cold solution of 5.8 g of (3RS,4RS)-1-tert.butyldimethylsilyl-3- (1-fluoro-1-methylethyl)-2-oxoazetidine-4-yl-(2-oxo)butyric-acid.4-nitro benzylester in 250 ml of methanol/water (9/1) are added 8.3 ml of conc. HCl. This mixture is stirred for 30 minutes at 0° and 5 hours at 25°. The methanol is removed by distillation and the product crystallised.
    [0164] E ) (5RS, 6SR)-3-(2-acetylaminoethylthio)-1-aza-6-(1-hydroxy-1-methylethyl)-7-oxobicyclo[3.2.0]hept-2-ene-2-carboxylic acid.4-nitrobenzylester (for example 3):
    [0165] To an ice-cold solution of 300 mg of (5RS,6SR)-1-aza-3,7-dioxo-6-(1-hydroxy-1-methylethyl)bicyclo[3.2.0]heptane-2-carboxylic acid.4-nitrobenzylester in 20 ml of abs. acetonitrile are added 0.22 ml of N-ethyldiisopropyl amine followed by 0.26 ml of phosphoric acid diphenyl ester chioride. After 15 minutes of 0° a further 0.22 ml of N-ethyldiisopropylamine are added followed by 140 mg of N-acetylcysteamine in 5 ml of abs. acetonitrile. Stirring is continued vor 1 hour at 0° and the reaction mixture partitioned between ethylacetate and saturated NaCl. The organic phase is dried ovor MgSO4 evaporated to dryness and tue residue chromatographed over silica gel (ethylacetate/acetone - 7/3).
    [0166] NMR (CDCI3): .1.36 (s, 3); 1.44 (s, 3): 2.00 (s, 3); 2.86-3.64 (m, 7); 4.28 (rd, 1 , J=9 and 2.7 Hz); 5.25 (d, 1, J 13.5 Hz); 5.56 (d, 1, J = 13.5 Hz); 5.92 (br, 1); 7.68 (d, 2, J = 9 Hz); 8.26 (d, 2, J = 9 Hz).
    [0167] F) (5R,6R)-1-aza-3,7-dioxo-6-[1(S)-fluorethyl]bicyclo[3.2.0]heptane-2- carboxylic acid.4-nitrobenzylester (for examples 23 and 24): a) 5(R)-[1-(S)fluorethyl]penicillanic acid methylester:
    [0168] To a suspension of 6.15 g of potassium fluoride in 200 ml abs. dichloromethane are added at -78° and under argon 10 ml of diethyl aminosulphur trifluoride. To this suspension is then added at -78° a solution of 12.5 g of 6-trans-[1-(R)hydroxyethyl]penicillanic acid methylester. After 45 minutes at -78° the cool-bath is removed and stirring continued for 1 hour at room temperature. The reaction mixture is extracted twice with water, dried over MgSO4 and concentrated. The residue is chromatographed on silica gel (dichloromethane) to yield the oily title compound.
    [0169] NMR(CDCl3): 1.48 (s, 3); 1.54 (dd, 3, J = 23.5 and 6.5 Hz); 1.65 (s, 3); 3.55 (ddd, 1, J = 28, 3.5 and 2 Hz); 3.79 (s, 3); 4.52 (s, 1): 5.03 (ddq, 1,J = 49, 6.5 and 3.5 Hz); 5.55 (d.1,J = 2 Hz). IR(CHCl3): 1770, 1750 cm-1
    [0170] b) (3R)-4-acetoxy-3-[1(S)-fluorethyl3-1-(3-methyl-2-ene-butyricacid- methylester-2-yl)-2-oxoazetidine
    [0171] To a solution of 7.1 g 6(R)-[1-(S)fluorethyl]penicillanic acid methylester in 200 ml of ethylacetate are added 21.7 g of mercuric acetate and stirring carried out for 1 hour at 100°. After cooling the mixture is filtered, evaporated to dryness and evaporated three tiraes with toluene. The residue is taken up in ethylacetate and the insoluable part filtered off. The filtrate is washed three times with 400 ml of water dried over MgSO4 and concentrated. The title compound crystallises. m.p. 94-97°.
    [0172] IR(CHCl3): 1770, 1720 cm-1.
    [0173] c) isopropylidene-[3(R)-(1-(S)fluorethyl)-4(R)-[2-(4-nitrobenzyloxy carbonylmethyl)allyl]-2-oxoazetidine-1-yl]acetic acid methylester
    [0174] To a solution of 6.5 g of (3R)-4-acetoxy-3-[1(S)-fluorethyl]-1-(3-methyl-2-ene-butyric acid methylester-2-yl)-2-oxoazetidine and 8.77 g of 3-methylene-4-trimethylsilylbutyric acid.4-nitrobenzylester (prepared according to K.ITOH et.al., Chem. Comm. 1977, 500) in 30 ml of nitromethane are added at -20° under argon and slowly 9.2 ml of trimethylsilyltriflate. After 15 minutes at -20° the cool bath is removed and stirring continued for 2 hours at room temperature. The mixture is diluted with 100 ml of ethylacetate, extracted with buffer solution (pH 7) dried over MgSO4 and evaporated to dryness. Chromatography over silica gel (dichloromethane/ether = 10/1) yields the oily title product.
    [0175] NMR(CDCI3): 1.54 (dd, 3, J = 24 and 7 Hz); 1.94 (s, 3); 2.20 (s, 3); 2.4 (dd, 1, J = 15 and 8.5 Hz); 2.56 (dd, 1, J = 15 and 5.5 Hz); 3.13 (ddd, 1,J = 24.5, 5.5 and 2.5 Hz); 3.14 (a, 2); 3.74 (s, 3); 4.17 (ddd, 1, J = 0.5, 5.5 and 2.5 Hz); 4.98 (dm, 1, J = 48 Hz); 5.02 (m, 2); 5.22 (s, 2); 7.52 (d, 2, J = 9 Hz); 8.22 (d, 2, J = 9 Hz).
    [0176] IR(CHCl3): 1750 cm-1. d) 4-[3(R)-(1(S)fluorethyl)-2-oxoazetidine-4(R)-yl]-3-oxobutyric-acid.4- nitrobenzylester:
    [0177] Ozone is passed through a solution of 850 mg of isopropylidene-[3(R)-(1- (S)fluorethyl)-4(R)—[2-(4—nitrobenzyloxycarbonylmethyl)allyl]-2-oxoaze tidine-1-yl]acetic acid methylester in 10ml of dichloromethane at -78° until the solution turns blue. Nitrogen is then added until colour is removed. After addition of 1 ml of dimethylsulfide the mixture is warmed to room temperature and stirred for 2 hours. Dichloromethane is removed and the residue dissolved in 5 ml of methanol and after addition of 1 drop of triethylamine stirred for 30 minutes. After removal of the solvent the residue is mixed with 200 ml of ether, extracted three times with water, dried over MgSO4 and concentrated. Chromatography over silica gel yields the oily title product.
    [0178] NMR(CDCI3): 1.52 (dd, 3, J = 24.5 and 7 Hz); 2.86-3.06 (m, 2); 3.07 (ddd, 1, J = 27, 3.5 and 2.7 Hz); 3.60 (s, 2); 4.01 (ddd, 1, J = 7.5, 6.5 and 2.7 Hz); 5.04 (dm, 1, J = 46 Hz); 5.30 (s, 2); 6.08 (br, 1); 7.56 (d, 2,J = 9 Hz); 0.29 (d, 2, J = 9 Hz). e) 4-[3(R)-(1-(S)fluorethyl)-2-oxoazetidine-4(R)-yl]-3-oxo-2-diazobutyric- acid.4-nitrobenzylester:
    [0179] To a solution of 100 mg of 4-[3(R)-(1-(S)fluorethyl)-2-oxoazetidine-4(R)-yl]-3-oxobutyric-acid.4-nitrobenzylester and 77 mg of 4-carboxybenzenesulphonylazide in 5 ml of acetonitrile are added dropwise under stirring and ice-cooling 0.31 ml of triethylamine and stirring then continued for 15 minutes at room temperature. The mixture is then diluted with 40 ml of ethylacetate, washed once with 5% bicarbonate solution and twice with water, dried over MgSO4 and concentrated to obtain the title compound.
    [0180] NMR(CDCl3): 1.52 (dd, 3, J = 2..5 and 7 Hz); 3.10 (dm, 1, J = 25 Hz); 3.17 (dd, 1, J = 18 and 8.5 Hz); 3.33 (dd, 1, J = 18 and 5 Hz); 4.02 (ddd, 1, J = 8.5, 5 and 2.5 Hz); 5.03 (dm, 1, J = 48.5 Hz); 5.39 (s, 2); 6.04 (br, 1); 7.58 (d, 2, J=9 Hz); 8.30 (d.2, J = 9 Hz). IR(CH2Cl2): 2150, 1770, 1720, 3675 cm-1. f) (5R,6R)-T-aza-3,7-dioxo-6-[1(S)-fluorethyl]bicyclo[3.2.0]heptane- 2-carboxylicacid.4-nitrobenzylester
    [0181] A solution of 100 mg of 4-[3(R)-(1-(S)fluoretbyl)-2-6xoazetidine-4(R)-yl]-3-oxo-2-diazobutyric-acid.4-nitrobenzylester in 20 ml of benzene is de-gassified by the vigorous passage of argon for 15 minutes with stirring. A catalytic quantity of rhodium(II)-acetate is added and the reaction vessel placed in a prewarmad 80° bath. After 15 minutes at 80° filtration is carried out and the filtrate concentrated to give the title product.
    [0182] NMR(CDCl3): 1.59 (dd, 3, J = 24 and 7 Hz); 2.50 (ad, 1, J = 18 and 8 Hz); 2.94 (dd, 1, J = 18 and 7 Hz); 3.43 (ddd, 1, J = 26, 4 and 2.5 Hz); 4.22 (td, 1, J = 7 and 2.5 Hz); 4.10-4.92 (m, 0.5); 4.80 (s, 1); 5.16-5.50 (m, 2-5); 7.56 (d, 2, J = 9 Hz); 8.30 (d, 2, J = 9 Hz). G ) N ,N , N ' , N ' - tetramethyl -N"- ( 2-mercapto )ethylguanidine. Hydroiodide ( for example 10)
    [0183] a) N,N,N' ,N'-tetramethyl-S-methylisothioureiciodide:
    [0184] To 100 ml of methyiiodide and 200 ml of dichloromethane are added with ice- cooling 30 g of tetramethylthiourea and the mixture then stirred for 3 hours in darkness and at room temperature. After the addition of 500 ml of ether the precipitated title compound (m.p.170°) can be directly further reacted. b ) N ,N , N' , N' - tetramethyl-N"-(2-mercapto)ethylguanidine. Hydroiodide A solution of 2.27 g of cysteamine HCl in 20 ml of abs. dimethylformamide is mixed at room temperature with 2.77 ml of triethylamine and stirred for 2 hours. The precipitate is removed and the filtrate mixed with 5.48 g of N,N,N' ,N'-tetramethyl-S-methylisothioureiciodide. After two hours of stirring at room temperature the mixture is mixed with 100 ml of diisopropylether and decanted from the resulting brown oil. This oil is digested with 10 ml of isopropanol whereupon the title compound crystallises. After filtration the residue is washed once with isopropano! and once with diisopropyl ether and dried to yield the title compound of m.p. 95°. NMR(CDCl3):2.10(br,1):2.90-3.30(m,14);3.42-3.70(m,2);7.66(br,1). IR(KBr):1615, 158.0 cm-1.
    [0185] H) N,N,N'-trimethylmercaptoacetamidine.Nonafluorobutanesulfonate (for example 12 ):
    [0186] a) α-tritylthio-N-methylacetamide To a solution of 26.55 g of sodium in 1800 ml of ethanol is added 288.8 g of tritylmercaptan. Then with ice-cooling a solution of 111.8 g of N-methylchloracetamide in 1000 ml of ethanol is added dropwise whereupon a grey-white precipitate is formed. After completion of the addition stirring is continued at room temperature for 45 minutes and the mixture then concentrated to half its volume. The precipitate is filtered, washed with isopropanol, water and again isopropanol and dried to give the title product. m.p. 200-210°.
    [0187] NMR(CDCl3):2.48(d,3, J=5.5Hz);3.13 (s,2):6.00 (br,1);7.10-7.60(m,15).
    [0188] b) α-tritylthio-N-methylthioacetamide
    [0189] 325 g of α-tritylthio-N-methylacetamide und 400 g Lawesson-Reagent are stirred for 6 hours in 4000 ml of toluene at 50°. After concentration to ca. 1300 ml the insoluble matter is removed and the residue washed with ethylacetate. The original filtrate and the ethyl acetate phase are combined and evaporated to dryness. The oily residue is made to crystalise by digestion with a little ethanol to give the ticle product more of which can be obtained by chromatography of the motner liquor over silica gel. NMR(CDCl3):2.75(d,3,J=5.5Hz);3.85(s,2);7.20-7.50(m,15);7.90(br,1). IR(KBr) : 1520,1440 , 1360 cm-1. c) α-tritylthio-N,S-dimethylacetic acid imidothioester. Hydroiodide
    [0190] 136 g of α-tritylthio-N-methylthioacetamide are stirred in darkness for 20 hours at room temperature in 800 ml of methyliodide. 1500 ml of ethylacetate are then added and the mixture filtered and washed through twice with ethylacetate to yield the title product. m.p. 130-140°.
    [0191] NHR(C2D2Cl4):2.20(s,3);3.08(s,3);3.77(s,2);7.20-7.60(m,15).
    [0192] IR(KBr):T600 cm-1. d) α-tritylthio-N,N,N'-trimethylacetamidine.Hydroiodide
    [0193] Dimethylamine is ccndensed over a dry-ice cooler into a suspension of 170 g of α-tritylthio-N,S-dimethylacetic acid imidothio ester. hydro iodide in 750 ml of abs. dichloromethane. with stirring at room temperature (ca. 200 ml ) and the by then clear solution stirred for a further 3 hours at room temperature. Evaporation to dryness is carried out and the residue brought to crystallisation by digestion with ethyl acetate. Filtration and drying yield the title product. m.p.190°.
    [0194] NMR(C2D2Cl4):2.80-3.06(m,9);3.32(s,2);7.25-7.60(m,15);8.58(br,1). IR(K.Br):1640 cm-1. e) N,N,N'-trimethylmercaptoacetamidine. Nonafluorobutanesulfonate
    [0195] 10 g of α-tritylthio-N,N,N'-trimethylacetamidinehydroiodide are partitioned between 6N NaOH and ether to yield the free base and then dissolved in 100 ml of methanol. At the same time a solution of 4.2 g of silver nitrite in 500 ml of methanol and 2.5 ml of pyridine is prepared. The solutions are combined and stirred for 90 minutes at room temperature. The resulting black-brown precipitate is filtered and washed through with methanol and ether. It is then suspended in 400 ml abs. dichloromethane to which is added 1 drop of pyridine and then for ca. 20 minutes at 0° H2S. After filtration through a glass frit the filtrate is concentrated, mixed with toluene and again evaporated to dryness. Following high-vacuum drying the residue is taken up in ca. 100 ml of 1N HCl and extracted three times with ethylacetate. 10 g of solid potassium nonafluorcbutane sulphonate are added and the mixture extracted 5 times with dichloromethane. After concentration of the combined extracts the title product crystal lines out. m.p. 60-65° (decomp.).
    [0196] NMR(CDCl3):2.42(br,1); 3.10-3.26(m,6);3.37(s,3);3.64(br,2);8.04 (br,1).
    [0197] IR(KBr):1650 cm-1.
    权利要求:
    ClaimsClaims:
    1. A 6-(1'-fluorethyl)- or 6-(1'-fluoro-1'-methylethyl)-carbapenem, with the exception of the compound (5RS, 6RS)-1-aza-6(1(R)-fluorethyl)-3-(2-acetaminoethylthio)-7-oxbbicyclo[3.2.0]hept-2-ene-2-carboxy!ic acid.
    2. Compounds of formula I
    wherein, R1 represen s hydrogen or methyl and
    R2 represents hydrogen or lower alkyl, lower alkenyl or cyclo- alkyl each of which may be unsubstituted or mono- or polysubstituted by amino, mono- or di-(lower)-alkylamino, lower acylamino, carboxy, lower alkoxycarbonyl or carbamoyl ; a group of formula IIc
    (CH2)p-R7 IIc wherein R7 represents phenyl or a 5- or 6-membered saturated or unsaturated heterocycle containing one or more heteroatoms selected from O, S and/or N and which may be unsubstituted or mono- or poly substituted by fluoro, chloro, bromo, amino, mono- or di-(lower)-alkylamino, hydroxy, lower alkoxy, mercapto, alkylthio, phenylthio, sulfamoyl, guanidino, nitro, cyano, lower acylamino, carboxyl , alkoxycarbonyl or carbamoyl and p is 0, 1, 2 or 3; or a group of formula
    wherein R4, R5 and R6 may be the same or different and each represents hydrogen or lower alkyl or R4 and R6 and/or R5 and one of the CH2 groups may be joined to form a ring as may R5 and R6 in formula II and R4 and R5 in Ila and Ilb, which rings may be unsubstituted or mono- or poly-substituted by alkyl, hydroxy, carboxy or di-(lower)-alkyl- amino , m is 2 or 3, and n is 1 , 2 or 3 with the proviso that when R1 is hydrogen and the group containing it has R-configuration, R2 is other than acetylaminoethyl; or protected forms and/or physiologically- hydrolysable and acceptable ester forms thereof; in free acid or salt form or in the form of zwitter-ions.
    3. A compound according to Claim 2 wherein R1 = hydrogen or methyl; R2 = lower alkyl, optionally mono- or disubstituted by amino, alkylamino, dialkylamino, acylamino, carboxy, imino, alkylimino and/or a heterocycle, e.g. methyltetrazolyl or morpholinyl.
    4. A compound according to Claim 3 selected from (5RS,6RS)-1-aza-6- (1(RS)-fluorethyl)-3-(N-dimethyl-N'-methylamidinomethylthio)-7-oxobicyclo-[3.2.0]hept-2-ene-2-carboxylic acid and (5RS,6RS)-1-aza-6-(1-(RS)-fluorethyl)-3-(N-dimethyl-amidinomethylthio]-7-oxobicyclo[3.2.0]hept-2-ene-2-carboxylic acid, or protected forms and/or physiologically-hydrolysable and acceptable ester forms thereof; in free acid or salt form or in the form of zwitter ions.
    5. A compound according to Claim 2 wherein R1 represents hydrogen and R2 represents hydrogen, lower alkyl, lower alkenyl, cycloalkyl which may be substituted by amino, mono- or di-(lower)-alkylamino, lower acylamino, carboxy, lower alkoxy carbonyl or carbamoyl whereby when a cycloalkyl group is substituted by amino or mono- or di- (lower)-alkylamino the nitrogen thereof may form part of the ring; or a group of formula II or Ila, wherein R4 , R5 and R6 may be the same or different and represent hydrogen or lower alkyl and m and n are as defined above and the carboxy group at position two is in free form or in protected or easily cleavable ester form or in the form of a salt with an organic or inorganic cation.
    6. A compound according to Claim 2 wherein R1 represents hydrogen or methyl , R2 represents hydrogen, lower alkyl, lower alkenyl, cycloalkyl which may be substituted by amino, mono- or di-(lower) alkylamino, lower acylamiπo, carboxy, lower alkoxy carbonyl or carbamoyl whereby when a cycloalkyl group is substituted by amino or mono- or di- (lower)-alkyl amino the nitrogen thereof may form part of the ring; a group of formula -(CH2)p-R7 wherein p represents 0, 1, 2 or 3 and R7 represents phenyl or a 5- or 6-membered, saturated or unsaturated heterocycle containing one or more heteroatoms selected from O, S and/or N; or a group of formula II or Ila wherein R4, R5 and R6 may be the same or different and represent hydrogen or lower alkyl and m and n are as defined above and the carboxy group at position two is in free form or in protected or easily cleavable ester form or in the form of a salt with an organic or inorganic cation.
    7. A chemotherapeutical composition comprising a compound as claimed in any one of Claims 1 to 6 or a chemotherapeutically acceptable salt or zwitter ion form thereof together with a chemotherapeutically acceptable diluent or carrier.
    8. A method of combating bacteria which comprises administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of Claims 1 to 6 or a chemotherapeutically acceptable salt or zwitter ion form thereof together with a chemotherapeutically acceptable diluent or carrier.
    9. A compound as claimed in any one of Claims 1 to 6 or a chemotherapeutically acceptable salt or zwitter ion form thereof together with a chemotherap utically acceptable diluent or carrier for use as a pharmaceutical.
    10. A process for preparing a compound according to Claim 1 which comprises exchanging hydroxy in a corresponding 6-(1'-hydroxyethyl)- or 6-(1'-hydroxy-1'-methylethyl)-carbapenem for fluorine.
    11. A process for preparing a compound according to Claim 2
    A) by introducing a group -S-R2 into a compound of formula III wherein R1 and R2 are as defined above,
    R8 represents a leaving group R3 represents a protecting group and a physiological ly hydrolysable and acceptable ester group or
    B) by exchanging the OH group in a compound of formula IV
    or a precursor thereof for fl uoro, whereby in formula IV, R1 , R2 and R3 are as defined above , and i f requi red deprotecting a compound thus obtained or if required converting a compound thus obtained into or into another physi ologi cal ly hydrolysable - and acceptable - ester form and/or protected form thereof and recovering the compound thus obtained in free aci d or sal t form or in the form of a zwi tterion.
    类似技术:
    公开号 | 公开日 | 专利标题
    US4524028A|1985-06-18|Monocyclic intermediates for thia-aza compounds with a β-lactam ring
    FI83419B|1991-03-28|Foerfarande foer framstaellning av som laekemedel anvaendbara 1,2,6-substituerad karbapen-2-em-3-karboxylsyra.
    CA1340273C|1998-12-15|6-substituted thia-aza compounds
    EP0182213B1|1990-09-26|Carbapenemverbindungen und deren Herstellung
    EP0058317B1|1986-08-27|Verfahren zur Herstellung von 2-Penem-Verbindungen
    US4282236A|1981-08-04|β-Lactam antibacterial agents, their use in pharmaceutical compositions, and intermediates
    EP0165384B1|1989-05-10|Carbapenem-Derivate, deren Herstellung und sie enthaltende Zusammensetzungen
    KR0133071B1|1998-04-17|2-|카르바페넴 유도체, 그의 제조방법 및 항생제로서의 그의 용도
    EP0001628B1|1984-01-18|3,6-Disubstituierte 7-oxo-1-azabicylo-|-2-hepten-2-carbonsäure, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
    EP0002564B1|1984-06-20|7-Oxo-1-azabicyclo-|-hepten-|-carbonsäure-|-Derivate, ihre Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und Zwischenprodukte
    EP0001627B1|1984-04-04|3-Substituierte 6-|-7-oxo-1-azabicyclo-|-2-hepten-2-carbonsäure, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
    US4260618A|1981-04-07|6-|-2-substituted-pen-2-em-3-carboxylic acid
    US4312871A|1982-01-26|6-, 1- And 2-substituted-1-carbadethiapen-2-em-3-carboxylic acids
    US4631150A|1986-12-23|Process for the preparation of penems
    NL8105470A|1982-07-01|1-sulfo 2-oxoazetidinederivaten, alsmede bereiding en toepassing daarvan.
    JPH0689004B2|1994-11-09|β―ラクタム化合物、その製法及びそれを含む医薬組成物
    US4640915A|1987-02-03|1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid derivatives
    US4234596A|1980-11-18|3-|-6-|-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
    GB2042515A|1980-09-24|Antibacterial agents
    OA6428A|1981-07-31|Composés de 2-penem, procédé de préparation et composition pharmaceutique obtenue.
    US4350631A|1982-09-21|6- and 4-Substituted-1-azabicyclo[3.2.0]heptan-3,7-dione-2-carboxylates
    EP0017992A1|1980-10-29|2-Substituierte-6-substituierte-1-Carbadethiapen-2-em-3-carbonsäuren, Verfahren zu ihrer Herstellung, sie enthaltende antibiotische pharmazeutische Zusammensetzungen und Verfahren zur Herstellung von Zwischenprodukten
    US4997829A|1991-03-05|Penem compounds, and use thereof
    JPH0853453A|1996-02-27|２−［１−（１，３−チアゾリン−２−イル）アゼチジン−３−イル］チオ−カルバペネム化合物
    KR100832287B1|2008-05-26|1-메틸카르바페넴 유도체
    同族专利:
    公开号 | 公开日
    FI832619A|1984-01-27|
    FI832619A0|1983-07-19|
    AT386600B|1988-09-12|
    FR2530634A1|1984-01-27|
    CH661729A5|1987-08-14|
    DK340483A|1984-01-27|
    ES524424D0||
    ATA903783A|1988-02-15|
    PT77094B|1986-02-26|
    CA1250839A|1989-03-07|
    PT77094A|1983-08-01|
    IT1194339B|1988-09-14|
    GB8319761D0|1983-08-24|
    HUT34029A|1985-01-28|
    NL8302619A|1984-02-16|
    SE8304124L|1984-01-27|
    CA1250839A1||
    GB2124625B|1986-03-19|
    SE8304124D0|1983-07-25|
    DK340483D0|1983-07-25|
    IL69324D0|1983-11-30|
    DE3390137T1|1984-09-20|
    GB2124625A|1984-02-22|
    DE3390137T0||
    FR2530634B1|1986-11-14|
    AU1724183A|1984-02-02|
    ES8506018A1|1985-06-16|
    US4720490A|1988-01-19|
    FI832619D0||
    IT8322230D0|1983-07-26|
    SE462492B|1990-07-02|
    ES524424A0|1985-06-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP0017992A1|1979-04-19|1980-10-29|Merck & Co., Inc.|2-Substituierte-6-substituierte-1-Carbadethiapen-2-em-3-carbonsäuren, Verfahren zu ihrer Herstellung, sie enthaltende antibiotische pharmazeutische Zusammensetzungen und Verfahren zur Herstellung von Zwischenprodukten|
    US4235922A|1979-06-15|1980-11-25|Merck & Co., Inc.|3--6-ethyl-7-oxo-1-azabicyclo [3.2.0]hept-2-ene-2-carboxylic acid|DE3434504A1|1983-10-03|1985-04-18|Sandoz Ag|Fluoralkylierte carbapenemderivate|
    EP0234484A1|1986-02-19|1987-09-02|Sanraku Incorporated|Azetidinonderivate|
    EP0774465A1|1995-11-20|1997-05-21|Suntory Limited|Penem-Derivate und diese enthaltende antimikrobielle Mittel|JPS6344754B2|1979-04-17|1988-09-06|Sanraku Co Ltd||
    US4372965A|1979-10-15|1983-02-08|Merck & Co., Inc.|6-, 1- And 2-substituted-thio-1-carbadethiapen-2-em-3-carboxylic acid S-oxides|
    IE52147B1|1980-03-27|1987-07-08|Merck & Co Inc|4--azetidin-2-ones and process for their preparation|
    US4309346A|1980-03-27|1982-01-05|Merck & Co., Inc.|Process for the preparation of 1-carbapenems and intermediates via trithioorthoacetates|
    DE3169321D1|1980-03-27|1985-04-25|Merck & Co Inc|Process for the preparation of 1-carbapenems and intermediates via silyl-substituted dithioacetals|
    EP0038869A1|1980-04-30|1981-11-04|Merck & Co., Inc.|Verfahren zur Herstellung von 1-Carbapenemen und Zwischenprodukte für ihre Herstellung|
    EP0044170A1|1980-07-11|1982-01-20|Beecham Group Plc|Beta-Lactam-Antibiotika, ihre Herstellung und Verwendung|
    PT73791B|1980-10-17|1983-10-14|Merck & Co Inc|Process for preparing 2-carbamimidoyl-6-substituted-1- -carbadethiapen-2-em-3-carboxylic acids|
    EP0060612A1|1981-02-04|1982-09-22|Beecham Group Plc|Verfahren zur Herstellung von Azabicyclo-hept-2-en-Derivaten|
    ES8404184A1|1981-08-03|1984-04-16|Merck & Co Inc|Un procedimiento para la prepracion de nuevos derivados de acidos 2-carbamimidoil-1-,carbadestiapen-2-en-3-carboxilados.|US4997936A|1977-10-19|1991-03-05|Merck & Co., Inc.|2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids|
    US4665169A|1985-09-11|1987-05-12|Bristol-Myers Company|Carbapenem antibiotics|
    US4948165A|1988-01-26|1990-08-14|Nissan Motor Company, Limited|Proportioning valve assembly for an actively controlled suspension system|
    US7932381B2|2005-02-15|2011-04-26|Shionogi & Co., Ltd.|Process for producing carbapenem derivative and intermediate crystal therefor|
    法律状态:
    1984-02-16| AK| Designated states|Designated state(s): AT CH DE |
    1984-03-21| ENP| Entry into the national phase|Ref document number: 1983 9037 Country of ref document: AT Date of ref document: 19840216 Kind code of ref document: A |
    1984-09-20| RET| De translation (de og part 6b)|Ref document number: 3390137 Country of ref document: DE Date of ref document: 19840920 |
    1984-09-20| WWE| Wipo information: entry into national phase|Ref document number: 3390137 Country of ref document: DE |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]